Aeglea BioTherapeutics, Inc./$SYRE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Aeglea BioTherapeutics, Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Ticker
$SYRE
Sector
Primary listing
Employees
95
Headquarters
Website
SYRE Metrics
BasicAdvanced
$1.7B
-
-$2.00
3.17
-
Price and volume
Market cap
$1.7B
Beta
3.17
52-week high
$25.06
52-week low
$10.91
Average daily volume
1.1M
Financial strength
Current ratio
10.905
Quick ratio
10.585
Profitability
Effective tax rate (TTM)
0.01%
Management effectiveness
Return on assets (TTM)
-30.20%
Return on equity (TTM)
-38.08%
Valuation
Price to book
4.55
Price to tangible book (TTM)
4.55
Price to free cash flow (TTM)
-8.22
Free cash flow yield (TTM)
-12.17%
Free cash flow per share (TTM)
-2.74
Growth
Earnings per share change (TTM)
-199.38%
3-year earnings per share growth (CAGR)
-58.37%
10-year earnings per share growth (CAGR)
-41.95%
Bulls say / Bears say
Robust balance sheet provides long runway, with $603.1 million in cash, cash equivalents, and marketable securities as of December 31, 2024, expected to fund operations into the second half of 2028 (PRNewswire).
Extensive clinical pipeline with positive interim Phase 1 PK and safety data for SPY001 reported in November 2024 and on-track data readouts for SPY002 in 2Q 2025 and SPY003 in 2H 2025, alongside a mid-2025 Phase 2 platform trial initiation in ulcerative colitis, underpins multiple upcoming value catalysts (PRNewswire).
Inclusion in the Nasdaq Biotechnology Index effective December 23, 2024 enhances Spyre’s visibility among biotech investors and may facilitate increased institutional interest (PRNewswire).
Continued net losses and high R&D spending signal an extended path to profitability, with Spyre reporting a $44.8 million net loss and $41.6 million in R&D expenses for Q1 2025, compared to $43.9 million and $34.9 million a year earlier (PRNewswire).
Frequent equity raises raise dilution concerns, as evidenced by the $275 million common stock offering priced at $18.50 per share in October 2025, suggesting ongoing reliance on shareholder financing to fund operations (GlobeNewswire).
Lack of commercial traction remains a headwind, with 0% earnings growth and a 100% drop in sales reported last quarter, underscoring revenue generation challenges at this stage (Investor’s Business Daily).
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aeglea BioTherapeutics, Inc. stock?
Aeglea BioTherapeutics, Inc. (SYRE) has a market cap of $1.7B as of November 11, 2025.
What is the P/E ratio for Aeglea BioTherapeutics, Inc. stock?
The price to earnings (P/E) ratio for Aeglea BioTherapeutics, Inc. (SYRE) stock is 0 as of November 11, 2025.
Does Aeglea BioTherapeutics, Inc. stock pay dividends?
No, Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders as of November 11, 2025.
When is the next Aeglea BioTherapeutics, Inc. dividend payment date?
Aeglea BioTherapeutics, Inc. (SYRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aeglea BioTherapeutics, Inc.?
Aeglea BioTherapeutics, Inc. (SYRE) has a beta rating of 3.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.